Clinical Report: PerioLase® MVP-7™ Nd:YAG Laser

Overview

The PerioLase® MVP-7™ Nd:YAG laser is the only device validated for the LANAP® protocol, promoting true periodontal regeneration. It boasts a high patient acceptance rate and offers financial benefits for practices through efficient treatment options.

Background

The management of periodontitis remains a critical area in dental care, with traditional methods like scaling and root planing (SRP) being the standard. The introduction of laser technologies, such as the PerioLase® MVP-7™, aims to enhance treatment outcomes and patient experiences. Understanding the efficacy and acceptance of these technologies is essential for clinicians considering their integration into practice.

Data Highlights

No numerical data available in the source material.

Key Findings

• The PerioLase® MVP-7™ is the only laser approved for the LANAP® protocol, which allows for true regeneration of the periodontal attachment apparatus.
• It has a 91% patient acceptance rate due to its minimally invasive approach, described as 'no cut, no sew, no fear.'
• The device is backed by a clinical guarantee of a 50% reduction in pocket depths for every patient treated.
• Practices can achieve significant financial benefits, with the potential for profit from treating just one patient per month.
• Training and mentorship are provided through the Institute for Advanced Laser Dentistry, enhancing clinician skills and treatment capabilities.

Clinical Implications

Clinicians considering the PerioLase® MVP-7™ should be aware of its unique capabilities in periodontal treatment and the potential for improved patient experiences. However, it is important to remain informed about the current guidelines and evidence regarding laser use in conjunction with traditional therapies.

Conclusion

The PerioLase® MVP-7™ Nd:YAG laser represents a significant advancement in periodontal treatment options, with strong patient acceptance and financial incentives for practices. Ongoing evaluation of its clinical efficacy in comparison to traditional methods is essential.

References

1. European Federation of Periodontology, Guideline on treatment of stage I-III periodontitis, 2026 -- Clinical Guidelines
2. Adjunctive low‐level laser therapy in periodontal treatment – A randomized clinical split-mouth trial, Clinical Oral Investigations, 2025 -- Research Article
3. Ophthalmology Management — Upgrades and Advances In Femto and Excimer Lasers
4. Ophthalmology Management — Upgrades and Advances In Femto and Excimer Lasers
5. Ophthalmology Management — SPOTLIGHT ON TECHNOLOGY & TECHNIQUE
6. Glaucoma Physician — Product Spotlight: Delivering Treatments Right on the Mark
7. Guideline on treatment of stage I-III periodontitis - European Federation of Periodontology
8. Adjunctive low‐level laser therapy in periodontal treatment – A randomized clinical split-mouth trial | Clinical Oral Investigations | Springer Nature Link
9. American Academy of Periodontology Best Evidence Consensus Statement on